Table 2. Distribution of VAP-1-targeting [⁶⁸Ga]DOTA-Siglec-9 in aortic cryosections, as determined by autoradiography.

	LDLR−/−ApoB100/100(n = 22)	LDLR−/−ApoB100/100 + competition (n = 5)	C57BL/6N controls(n = 20)
Plaque	37 ± 16	17 ± 10 P = 0.026*	ND
Wall	18 ± 9	10 ± 5 P = 0.086*	13 ± 7 P = 0.17†
Adventitia	21 ± 10	8 ± 4 P = 0.016*	14 ± 7 P = 0.017†
Plaque-to-wall	2.1 ± 0.43 P < 0.0001**	1.7 ± 0.13 P = NS**	ND
Plaque-to-adventitia	1.8 ± 0.35 P < 0.0001**	2.3 ± 0.75 P = NS**	ND
Wall-to-adventitia	0.83 ± 0.12 P < 0.0001**	1.3 ± 0.34 P = NS**	0.94 ± 0.16 P = 0.072**

Results are expressed as photostimulated luminescence per square millimeter or as ratios (mean ± SD). The competition assay was performed by pre-injecting unlabeled Siglec-9 peptide prior to injection of [⁶⁸Ga]DOTA-Siglec-9.

ND, not determined.

^*LDLR^−/−ApoB^100/100vs. LDLR^−/−ApoB^100/100 + competition, non-paired t test.

^†LDLR^−/−ApoB^100/100vs. C57BL/6N controls, non-paired t test.

^**P value, paired t test.